AETERNUM HEALTH, INC. agreed to pay Josua Oosthuizen an annual base salary of $240,000 as CEO. Oosthuizen is eligible for an annual Bonus of up to 60% and four $200,000 cash awards tied to US GAAP-based average monthly Revenue targets of $3 million, $6 million, $9 million and $12 million.
Key Highlights
- Josua Oosthuizen will serve as AETERNUM HEALTH, INC.’s CEO for two years under the employment agreement.
- His annual base salary is $240,000, with eligibility for an annual bonus of up to 60% of base salary.
- Four milestone awards of $200,000 each are tied to escalating US GAAP-based revenue thresholds.
AETERNUM HEALTH, INC. Agreed to pay Josua Oosthuizen an annual base salary of $240,000 under an employment agreement for his role as CEO. Oosthuizen also qualifies for annual bonus compensation and additional cash awards linked to US GAAP-based revenue performance. The agreement was entered into on July 31, 2026.
CEO Agreement Sets Revenue-Based Cash Awards
The annual bonus can reach 60% of Oosthuizen’s base salary. The parent will pay 100% of the cost of elected group medical, vision and dental coverage, as well as 100% of the additional incremental cost for family coverage. The agreement also includes confidentiality, indemnification and directors’ and officers’ Liability Insurance provisions.
FAQs
Q: What is Aeternum Health CEO Josua Oosthuizen’s salary?
A: Josua Oosthuizen’s annual base salary under the AETERNUM HEALTH CEO employment agreement is $240,000. He is also eligible for annual bonus compensation.
Q: How is AETERNUM HEALTH CEO compensation structured?
A: Compensation includes a base salary, an annual bonus of up to 60% of base salary and milestone cash awards tied to US GAAP-based revenue targets.
Q: What revenue targets trigger Aeternum Health CEO bonuses?
A: Four $200,000 milestone awards are tied to average monthly revenues of $3 million, $6 million, $9 million and $12 million over trailing three-month periods.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.